As new government figures show that prescriptions for antidepressants have increased by 33 per cent in the last six years, costing the UK economy over £28 million, a mental health charity today says it has been awarded £95,000 by the Department of Health to promote exercise as an effective treatment for mild to moderate depression.
While unemployment rates are monitored regularly and play a crucial role in shaping government monetary policy, the hidden economic impact of depression and anxiety may be just as significant: it turns out that more people receive government benefits as a result of severe depression and anxiety than receive benefits for being unemployed. Experts are urging the government to fund 200 new treatment centres to offer psychological therapy to those affected.
The anti-obesity drug rimonabant hasn’t even been approved for sale yet in the European Union, yet counterfeit versions of the drug are already being sold illegally over the internet, using the drug’s proposed brand name Accomplia. The EU Commission has warned bluntly: “Patients who buy unlicensed and counterfeit or illicit copies of rimonabant may be putting their health at risk”.
Individuals with bipolar I or II major depression are often misdiagnosed as having unipolar major depression. But a new screening method, testing just three factors, promises to help distinguish between those suffering from bipolar disorder and unipolar major depression.
The authors of a two-year inquiry, backed by the Mental Health Foundation and the Camelot Foundation, have called on the UK Government to launch a national initiative to develop better and more appropriate responses to young people who self-harm, starting with an awareness campaign targeted at professionals, parents and young people.
We comply with the HONcode standard for trustworthy health information: verify here.
